Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

Trial Profile

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Islatravir (Primary) ; Doravirine; Doravirine/lamivudine/tenofovir disoproxil fumarate; Lamivudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DRIVE2Simplify
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Oct 2019 Planned End Date changed from 22 Oct 2020 to 7 Apr 2021.
    • 15 Oct 2019 Planned primary completion date changed from 22 Oct 2020 to 7 Apr 2021.
    • 24 Jul 2019 According to an Merck & Co media release, this Phase 2b study continues with additional measures to be taken at Week 96 and beyond.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top